Nateglinide 那格列奈
CAS 105816-04-4 MFCD00875706
                 信息真实价格透明   
                 资金保障   
                 专业采购外包团队在线服务   
                
                
                 信息真实价格透明   
                 资金保障   
                 专业采购外包团队在线服务   
                  
                
                 品牌质保精细包装   
                 现货库存   
                 一流品牌服务   
                
            分类
- {SNA} Approved Therapeutics/Drug Candidates, Bioactive Small Molecules, Calcium Channel Modulators, Cell Biology, Cell Signaling and Neuroscience, Inhibitors and Activators, Ion Channels, N, Novartis, Voltage-gated Ion Channels
 - {SNA} Approved Therapeutics/Drug Candidates, Bioactive Small Molecule Alphabetical Index, Calcium Channel Modulators, Inhibitors and Activators, Ion Channels, N, Novartis, Voltage-gated Ion Channels, 生物活性小分子, 细胞信号转导和神经科学, 细胞生物学
 
相关文献及参考
- [2]. Shiling Hu, et al. Interaction of nateglinide with KATP channel in h-cells underlies its unique insulinotropic action. European Journal of Pharmacology. 442 (2002) 163-171.
 - [3]. Jian Luo, et al. Evaluating insulin secretagogues in a humanized mouse model with functional human islets. Metabolism. 2013 Jan;62(1):90-9.
 - [4]. Duffy NA, et al. Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1. Eur J Pharmacol. 2007 Jul 30;568(1-3):278-86.
 - [1]. Christopher J. Dunn, et al. Nateglinide. OFILE Drugs 2000 Sep: 60 (3): 6.
 - [1]. Christopher J. Dunn, et al. Nateglinide. OFILE Drugs 2000 Sep: 60 (3): 6.
 - [2]. Shiling Hu, et al. Interaction of nateglinide with KATP channel in h-cells underlies its unique insulinotropic action. European Journal of Pharmacology. 442 (2002) 163-171.
 - [3]. Jian Luo, et al. Evaluating insulin
 
安全信息
 GHS Symbol 
        
            
            TYPE OF TEST : LD - Lethal dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >2 gm/kg TOXIC EFFECTS : Sense Organs and Special Senses (Eye) - ptosis Behavioral - somnolence (general depressed activity) Gastrointestinal - hypermotility, diarrhea REFERENCE : YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 25(Suppl 1),S5,1997
TYPE OF TEST : LD - Lethal dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Mammal - dog DOSE/DURATION : >2 gm/kg TOXIC EFFECTS : Gastrointestinal - nausea or vomiting REFERENCE : YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 25(Suppl 1),S9,1997
TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Rodent - rat
DOSE                    : 27 gm/kg
SEX/DURATION            : female 17-22 day(s) after conception
                          lactating female 1-21 day(s) post-birth
TOXIC EFFECTS :
   Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight
   gain)
REFERENCE :
   YACHDS Yakuri to Chiryo.  Pharmacology and Therapeutics.  (Raifu Saiensu
   Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan)  V.1-    1972-
   Volume(issue)/page/year: 25(Suppl 1),S139,1997